Medical Patent Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Urokinase
Microbix Provides Update on Urokinase Project Financing
April 11th, 2007
Microbix Biosystems Inc. (TSX:MBX) announced that several parties have expressed strong interest in financing the continuing development of the Company's Urokinase product for use in dissolving blood clots and cancer therapies. Microbix expects financing to be in place in 2007. The funds will be used to conduct clinical trials and proceed to commercialization. "This interest in Urokinase reflects its value as a platform for a number of indications we are pursuing," said Company Chairman and CEO William J. Gastle. As a thrombolytic, or 'clot-busting' drug, Urokinase has benefited more than five million patients and has had an...
Source: Medical Patent Law Weekly (2007-04-11)
|
